Our first annual M&A report analyzes deal flow, sector trends and more using data sourced in a new way to produce the most accurate look at M&A in the industry. You can read about our research methodology here, but to catch several highlights of the report, scan the salient points below or watch the report's author recap above. If that isn't quite enough M&A analysis to satisfy you, download the report here.
Join the 300,000+ professionals who receive our daily newsletters. Subscribe for free by
2014's big increase in value was due to a wave of billion-dollar-plus deals, particularly in the pharma and telecom spaces. Overall, 287 deals of $1 billion or more were made last year, 29% more than 2013.
Many of those mega-deals happened in the pharmaceuticals industry, as drug companies scrambled to buy up rival companies to restock their pipelines and cushion possible losses due to expiring drug patents. That wave more than doubled total M&A deal value in the healthcare industry last year.
Only 37% of 2014 take-privates went to private equity buyers, down from 41% in 2013. We expect that trend to continue as long as stock prices remain high.
PE firms are selling to strategics in large numbers. More than $275 billion of PE capital exited went to corporate acquisitions, up 72% from 2013 levels.